阿尔茨海默病中TOMM40基因改变的两年随访研究
TOMM40 alterations in Alzheimer's disease over a 2-year follow-up period.
作者信息
Goh Liang Kee, Lim Wee Shiong, Teo Stephanie, Vijayaraghavan Aadhitthya, Chan Mark, Tay Laura, Ng Tze Pin, Tan Chay Hoon, Lee Tih Shih, Chong Mei Sian
机构信息
Centre for Quantitative Medicine, Duke-NUS Graduate Medical School, Singapore, Singapore.
Department of Geriatric Medicine, Tan Tock Seng Hospital, Singapore, Singapore Institute of Geriatrics and Active Ageing, Tan Tock Seng Hospital, Singapore, Singapore.
出版信息
J Alzheimers Dis. 2015;44(1):57-61. doi: 10.3233/JAD-141590.
We previously reported TOMM40 to be significantly down-regulated in whole blood of Alzheimer's disease (AD) subjects at baseline and after one-year. In this longitudinal follow-up study of TOMM40 expression up to 2 years, we performed 6-monthly assessments for the first year and 2nd year blood sampling on 27 probable AD subjects compared with age- and gender-matched controls. TOMM40 gene expression remained significantly lower in AD patients at all time-points compared to controls, supported by confirmatory RT-PCR results. Our findings of consistently lower TOMM40 expression on longitudinal 2-year sampling support its potential role as a diagnostic blood AD biomarker.
我们之前报道过，在基线时以及一年后，转位酶线粒体40（TOMM40）在阿尔茨海默病（AD）患者的全血中显著下调。在这项对TOMM40表达长达2年的纵向随访研究中，我们对27名可能患有AD的受试者进行了为期2年的研究，在第一年每6个月进行一次评估，并在第二年对其进行血液采样，同时与年龄和性别匹配的对照组进行比较。与对照组相比，在所有时间点AD患者的TOMM40基因表达均显著降低，这得到了验证性逆转录聚合酶链反应（RT-PCR）结果的支持。我们在长达2年的纵向采样中发现TOMM40表达持续较低，这支持了其作为AD血液诊断生物标志物的潜在作用。
Zotero 插件